Impressed with a 50% success rate? Witnessing blinding acute angle attacks motivated Dr Judy Ku’s passion for primary angle closure disease. She explores how a 50% success rate sounds impressive, but its real-world outcomes are less, especially when factoring in the economic costs of large population screening and proactive treatment. So, while laser peripheral iridotomy is effective in reducing the risk progression to primary angle closure and acute angle closure attacks – what are the...
All content for Women in Ophthalmology - 10 Minutes of Science is the property of Women in Ophthalmology and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Impressed with a 50% success rate? Witnessing blinding acute angle attacks motivated Dr Judy Ku’s passion for primary angle closure disease. She explores how a 50% success rate sounds impressive, but its real-world outcomes are less, especially when factoring in the economic costs of large population screening and proactive treatment. So, while laser peripheral iridotomy is effective in reducing the risk progression to primary angle closure and acute angle closure attacks – what are the...
S01E04 Eplerenone for Chronic Central Serous Chorioretinopathy in Patients with Active, Previously Untreated Disease for more than 4 Months (VICI)
Women in Ophthalmology - 10 Minutes of Science
11 minutes
3 years ago
S01E04 Eplerenone for Chronic Central Serous Chorioretinopathy in Patients with Active, Previously Untreated Disease for more than 4 Months (VICI)
Eplerenone for Chronic Central Serous Chorioretinopathy in Patients with Active, Previously Untreated Disease for more than 4 Months (VICI): A Randomised, Double-blind, Placebo-controlled TrialThe VICI trial is highly topical. Dr Narme Deva, Consultant Ophthalmologist & Honorary Senior Lecturer at the University of Auckland, explores the Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised...
Women in Ophthalmology - 10 Minutes of Science
Impressed with a 50% success rate? Witnessing blinding acute angle attacks motivated Dr Judy Ku’s passion for primary angle closure disease. She explores how a 50% success rate sounds impressive, but its real-world outcomes are less, especially when factoring in the economic costs of large population screening and proactive treatment. So, while laser peripheral iridotomy is effective in reducing the risk progression to primary angle closure and acute angle closure attacks – what are the...
